Persistent asthma: patient characteristics, courses of asthma, and utility of salmeterol.
Applications of National Asthma and Education and Prevention Program (NAEPP) guidelines for the diagnosis and management of asthma may reduce the morbidity of this disorder. Medical records and questionnaires from a series of 177 outer-city adolescents and adults with persistent asthma were audited according to NAEPP guidelines and for utility of salmeterol (Serevent). Allergic sensitivity and exposure to indoor allergens house-dust mite (66% of patients), fungi (42%), cat (20%) and/or dog (14%) were of dominant importance to persistent asthma. Patients who continued salmeterol over 1 year had reduced severity of disease, improved forced expiratory flow at 25%-75% of vital capacity, and reduced usage of systemic, but not inhaled, corticosteroid.
Mathison
D A
DA
Division of Allergy, Asthma and Immunology Scripps Clinic, La Jolla, California 92037, USA.
Koziol
J A
JA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000485:Allergens / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002415:Cats; D002648:Child; D004285:Dogs; D005260:Female; D005540:Forced Expiratory Flow Rates; D006801:Humans; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D008925:Mites; D012130:Respiratory Hypersensitivity / Q000276:immunology; D000068299:Salmeterol Xinafoate; D011795:Surveys and Questionnaires; D014797:Vital Capacity
D000485:Allergens; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol